DOCSLIB.ORG

SJH Procedures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SJH Procedures SJH Procedures - Gynecology and Gynecology Oncology Services New Name Old Name CPT Code Service ABLATION, LESION, CERVIX AND VULVA, USING CO2 LASER LASER VAPORIZATION CERVIX/VULVA W CO2 LASER 56501 Destruction of lesion(s), vulva; simple (eg, laser surgery, Gynecology electrosurgery, cryosurgery, chemosurgery) 56515 Destruction of lesion(s), vulva; extensive (eg, laser surgery, Gynecology electrosurgery, cryosurgery, chemosurgery) 57513 Cautery of cervix; laser ablation Gynecology BIOPSY OR EXCISION, LESION, FACE AND NECK EXCISION/BIOPSY (MASS/LESION/LIPOMA/CYST) FACE/NECK General, Gynecology, Plastics, ENT, Maxillofacial BIOPSY OR EXCISION, LESION, FACE AND NECK, 2 OR MORE EXCISE/BIOPSY (MASS/LESION/LIPOMA/CYST) MULTIPLE FACE/NECK 11102 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, single lesion Aesthetics, Urology, Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11103 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, each separate/additional lesion (list separately in addition to Aesthetics, Urology, code for primary procedure) Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11104 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); single lesion Aesthetics, Urology, Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11105 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); each separate/additional lesion (list separately in Aesthetics, Urology, addition to code for primary procedure) Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11106 Incisional biopsy of skin (eg, wedge) (including simple closure, General, Gynecology, when performed); single lesion Aesthetics, Urology, Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11107 Incisional biopsy of skin (eg, wedge) (including simple closure, General, Gynecology, when performed); each separate/additional lesion (list Aesthetics, Urology, separately in addition to code for primary procedure) Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics BIOPSY OR EXCISION, LESION, LOWER BODY EXCISE/BIOPSY (MASS/LESION/LIPOMA/CYST) LOWER BODY General, Gynecology, Orthopedics, Plastics, Urology, Neurosurgery, Aesthetics, Colorectal, Spine, Vascular, Podiatry BIOPSY OR EXCISION, LESION, LOWER BODY, 2 OR MORE EXCISE/BIOPSY (MASS/LESION/LIPOMA/CYST) MULTIPLE LOWER BODY 11102 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, single lesion Orthopedics, Plastics, Urology, Aesthetics, Vascular, Maxillofacial, Thoracic, Cardiovascular, ENT, Colorectal, Podiatry Page 1 of 20 * Indicates Inpatient only CPT Code/Procedure SJH Procedures - Gynecology and Gynecology Oncology Services New Name Old Name CPT Code Service BIOPSY OR EXCISION, LESION, LOWER BODY, 2 OR MORE EXCISE/BIOPSY (MASS/LESION/LIPOMA/CYST) MULTIPLE LOWER BODY 11103 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, each separate/additional lesion (list separately in addition to Orthopedics, Plastics, Urology, code for primary procedure) Aesthetics, Vascular, Maxillofacial, Thoracic, Cardiovascular, ENT, Colorectal, Podiatry 11104 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); single lesion Orthopedics, Plastics, Urology, Aesthetics, Vascular, Maxillofacial, Thoracic, Cardiovascular, ENT, Colorectal, Podiatry 11105 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); each separate/additional lesion (list separately in Orthopedics, Plastics, Urology, addition to code for primary procedure) Aesthetics, Vascular, Maxillofacial, Thoracic, Cardiovascular, ENT, Colorectal, Podiatry 11106 Incisional biopsy of skin (eg, wedge) (including simple closure, General, Gynecology, when performed); single lesion Orthopedics, Plastics, Urology, Aesthetics, Vascular, Maxillofacial, Thoracic, Cardiovascular, ENT, Colorectal, Podiatry 11107 Incisional biopsy of skin (eg, wedge) (including simple closure, General, Gynecology, when performed); each separate/additional lesion (list Orthopedics, Plastics, Urology, separately in addition to code for primary procedure) Aesthetics, Vascular, Maxillofacial, Thoracic, Cardiovascular, ENT, Colorectal, Podiatry BIOPSY OR EXCISION, LESION, UPPER BODY EXCISION/BIOPSY ( MASS/LESION/LIPOMA/CYST) UPPER BODY General, Gynecology, Orthopedics, Plastics, ENT BIOPSY OR EXCISION, LESION, UPPER BODY, 2 OR MORE EXCISE/BIOPSY (MASS/LESION/LIPOMA/CYST) MULTIPLE UPPER BODY 11102 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, single lesion Orthopedics, Plastics, Aesthetics, Cardiac/Thoracic Robotics, Cardiovascular, Colorectal, ENT, Maxillofacial, Spine, Vascular 11103 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, each separate/additional lesion (list separately in addition to Orthopedics, Plastics, code for primary procedure) Aesthetics, Cardiac/Thoracic Robotics, Cardiovascular, Colorectal, ENT, Maxillofacial, Spine, Vascular 11104 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); single lesion Orthopedics, Plastics, Aesthetics, Cardiac/Thoracic Robotics, Cardiovascular, Colorectal, ENT, Maxillofacial, Spine, Vascular Page 2 of 20 * Indicates Inpatient only CPT Code/Procedure SJH Procedures - Gynecology and Gynecology Oncology Services New Name Old Name CPT Code Service BIOPSY OR EXCISION, LESION, UPPER BODY, 2 OR MORE EXCISE/BIOPSY (MASS/LESION/LIPOMA/CYST) MULTIPLE UPPER BODY 11105 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); each separate/additional lesion (list separately in Orthopedics, Plastics, addition to code for primary procedure) Aesthetics, Cardiac/Thoracic Robotics, Cardiovascular, Colorectal, ENT, Maxillofacial, Spine, Vascular 11106 Incisional biopsy of skin (eg, wedge) (including simple closure, General, Gynecology, when performed); single lesion Orthopedics, Plastics, Aesthetics, Cardiac/Thoracic Robotics, Cardiovascular, Colorectal, ENT, Maxillofacial, Spine, Vascular 11107 Incisional biopsy of skin (eg, wedge) (including simple closure, General, Gynecology, when performed); each separate/additional lesion (list Orthopedics, Plastics, separately in addition to code for primary procedure) Aesthetics, Cardiac/Thoracic Robotics, Cardiovascular, Colorectal, ENT, Maxillofacial, Spine, Vascular CERCLAGE, CERVIX CERCLAGE CERVICAL 57700 Cerclage of uterine cervix, nonobstetrical Gynecology 59320 Cerclage of cervix, during pregnancy; vaginal Gynecology *59325 Cerclage of cervix, during pregnancy; abdominal Gynecology CHROMOPERTUBATION, LAPAROSCOPIC CHROMOTUBATION LAPAROSCOPY 58350 Chromotubation of oviduct, including materials Gynecology CLOSURE, FISTULA, VESICOVAGINAL FISTULECTOMY VESICOVAGINAL *51900 Closure of vesicovaginal fistula, abdominal approach Gynecology 57320 Closure of vesicovaginal fistula; vaginal approach Gynecology 57330 Closure of vesicovaginal fistula; transvesical and vaginal Gynecology approach COLPOCLEISIS COLPOCLEISIS VAGINAL 57120 Colpocleisis (Le Fort type) Gynecology COLPOPEXY, ABDOMINAL APPROACH SUSPENSION VAGINAL VAULT (ABDOMINAL APPROACH) *57280 Colpopexy, abdominal approach Gynecology COLPORRHAPHY COLPORRHAPHY 57200 Colporrhaphy, suture of injury of vagina (nonobstetrical) Gynecology 57240 Anterior colporrhaphy, repair of cystocele with or without Gynecology repair of urethrocele, including cystourethroscopy, when performed 57250 Posterior colporrhaphy, repair of rectocele with or without Gynecology perineorrhaphy 57260 Combined anteroposterior colporrhaphy, including Gynecology cystourethroscopy, when performed; COLPORRHAPHY, ANTERIOR, USING MESH IF INDICATED REPAIR ANTERIOR W/WO MESH 57240 Anterior colporrhaphy, repair of cystocele with or without Gynecology repair of urethrocele, including cystourethroscopy, when performed 57267 Insertion of mesh or other prosthesis for repair of pelvic floor Gynecology defect, each site (anterior, posterior compartment), vaginal approach (List separately in addition to code for primary procedure) COLPORRHAPHY, ANTERIOR, WITH COLPORRHAPHY POSTERIOR AND/OR REPAIR ANTERIOR &/ POSTERIOR &/ ENTEROCELE W SLING 57240 Anterior colporrhaphy, repair of cystocele with or without Gynecology ENTEROCELE REPAIR IF INDICATED, WITH SUBURETHRAL SLING CREATION repair of urethrocele, including cystourethroscopy, when performed Page 3 of 20 * Indicates Inpatient only CPT Code/Procedure SJH Procedures - Gynecology and Gynecology Oncology Services New Name Old Name CPT Code Service COLPORRHAPHY, ANTERIOR, WITH COLPORRHAPHY POSTERIOR AND/OR REPAIR ANTERIOR &/ POSTERIOR &/ ENTEROCELE W SLING 57250 Posterior colporrhaphy, repair of rectocele with or without Gynecology ENTEROCELE REPAIR IF INDICATED, WITH SUBURETHRAL SLING CREATION perineorrhaphy 57260 Combined anteroposterior colporrhaphy, including Gynecology cystourethroscopy, when performed; 57265 Combined anteroposterior colporrhaphy, including Gynecology cystourethroscopy, when performed; with enterocele repair 57268 Repair of enterocele, vaginal approach (separate procedure) Gynecology *57270 Repair of enterocele, abdominal approach (separate Gynecology procedure) 57288 Sling operation for stress incontinence (eg, fascia or synthetic) Gynecology COLPORRHAPHY, COMBINED ANTEROPOSTERIOR, WITH CYSTOSCOPY, REPAIR
Load more

Recommended publications
  • Hysteroscopy with Dilation and Curretage (D & C)
    501 19th Street, Trustees Tower FORT SANDERS WOMEN’S SPECIALISTS 1924 Pinnacle Point Way Suite 401, Knoxville Tn 37916 P# 865-331-1122 F# 865-331-1976 Suite 200, Knoxville Tn 37922 Dr. Curtis Elam, M.D., FACOG, AIMIS, Dr. David Owen, M.D., FACOG, Dr. Brooke Foulk, M.D., FACOG Dr. Dean Turner M.D., FACOG, ASCCP, Dr. F. Robert McKeown III, M.D., FACOG, AIMIS, Dr. Steven Pierce M.D., Dr. G. Walton Smith, M.D., FACOG, Dr. Susan Robertson, M.D., FACOG HYSTEROSCOPY WITH DILATION AND CURRETAGE (D & C) Please read and sign the following consent form when you feel that you completely understand the surgical procedure that is to be performed and after you have asked all of your questions. If you have any further questions or concerns, please contact our office prior to your procedure so that we may clarify any pertinent issues. Definition: HysterosCopy is an outpatient procedure that allows your doctor direct visualization of the inside of the uterine cavity (womb) by inserting a thin lighted telescope (hysteroscope) through the vagina (birth canal) and cervix, without making an abdominal incision. This procedure enables your doctor to examine the lining of the uterus, look for polyps, fibroids, scar tissue, blockages of the fallopian tubes, and abnormal partitions. In addition, this procedure allows your doctor to remove or surgically treat many of the abnormalities seen. Dilation and Curettage (D&C) allows your doctor to take a sample of the tissue that lines your uterus (endometrium) and/or to remove polyps, fibroid tumors, or hyperplasia. Suction D&C is used in cases of miscarriage.
    [Show full text]
  • Gyn Oncology Colposcopy I. Basic Science/Mechanisms of Disease A
    Gyn Oncology Colposcopy I. Basic Science/Mechanisms of Disease A. Genetics 1. Describe the clinical relevance of viral oncogenes. 2. Describe the role of aneuploidy in the pathogenesis of neoplasia. 3. Describe the inheritance patterns for malignancies of the pelvic organs and breast. 4. Describe the cell replication cycle, and identify the phases of the cycle most sensitive to radiation and chemotherapy. 5. Describe the genetic basis for tumor immunotherapy. B. Physiology 1. Describe the ability of vital organ systems to tolerate cancer therapy. 2. Describe the changes in cellular physiology that result from injury due to radiation and chemotherapy. 3. Describe the metabolic changes that occur in patients with a malignancy of the pelvic organs or breast. C. Embroyology 1. Describe the embryology of gonadal migration and its role in the pathogenesis of epithelial cell tumors. 2. Describe the pathogenesis of gonadal tumors in patients with gonadal dysgenesis. 3. Describe the embryologic precursors of ovarian germ cell tumors. D. Anatomy 1. Describe the gross histologic anatomy of the pelvic organs and breast. 2. Describe the vascular, lymphatic, and nerve supply to each of the pelvic organs. 3. Describe the anatomic relationship between the reproductive organs and other viscera, such as bladder, ureters, and bowel. 4. Describe the likely changes in the anatomic relationships of the pelvic and abdominal viscera created by surgical or radiation treatment for malignancy. E. Pharmacology 1. List major chemotherapeutic agents used for treatment of malignancies of the reproductive organs and breast. 2. Describe the principal adverse effects of the major chemotherapeutic agents. 3. Describe the medications of most value in treatment of complications resulting from chemotherapy and irradiation, such as: a.
    [Show full text]
  • Physiology of Female Sexual Function and Dysfunction
    International Journal of Impotence Research (2005) 17, S44–S51 & 2005 Nature Publishing Group All rights reserved 0955-9930/05 $30.00 www.nature.com/ijir Physiology of female sexual function and dysfunction JR Berman1* 1Director Female Urology and Female Sexual Medicine, Rodeo Drive Women’s Health Center, Beverly Hills, California, USA Female sexual dysfunction is age-related, progressive, and highly prevalent, affecting 30–50% of American women. While there are emotional and relational elements to female sexual function and response, female sexual dysfunction can occur secondary to medical problems and have an organic basis. This paper addresses anatomy and physiology of normal female sexual function as well as the pathophysiology of female sexual dysfunction. Although the female sexual response is inherently difficult to evaluate in the clinical setting, a variety of instruments have been developed for assessing subjective measures of sexual arousal and function. Objective measurements used in conjunction with the subjective assessment help diagnose potential physiologic/organic abnormal- ities. Therapeutic options for the treatment of female sexual dysfunction, including hormonal, and pharmacological, are also addressed. International Journal of Impotence Research (2005) 17, S44–S51. doi:10.1038/sj.ijir.3901428 Keywords: female sexual dysfunction; anatomy; physiology; pathophysiology; evaluation; treatment Incidence of female sexual dysfunction updated the definitions and classifications based upon current research and clinical practice.
    [Show full text]
  • Curative Pelvic Exenteration for Recurrent Cervical Carcinoma in the Era of Concurrent Chemotherapy and Radiation Therapy
    Available online at www.sciencedirect.com ScienceDirect EJSO xx (2015) 1e11 www.ejso.com Review Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review H. Sardain a,b, V. Lavoue a,b,c,*, M. Redpath d, N. Bertheuil b,e, F. Foucher a,J.Lev^eque a,b,c a CHU de Rennes, Gynecology Department, Tertiary Surgery Center, Teaching Hospital of Rennes, Hopital^ Sud, 16, Bd de Bulgarie, 35000 Rennes, France b Universite de Rennes, Faculty of Medicine, 2 Henry Guilloux, 35000 Rennes, France c INSERM, ER440, Oncogenesis, Stress and Signaling (OSS), Rennes, France d McGill University, Department of Pathology, Jewish General Hospital, Cote^ Sainte Catherine, Montreal, QC, Canada e CHU de Rennes, Department of Plastic, Reconstructive and Aesthetic Surgery, Tertiary Surgery Center, Teaching Hospital of Rennes, Hopital^ Sud, 16, Bd de Bulgarie, 35000 Rennes, France Accepted 26 March 2015 Available online --- Abstract Objective: Pelvic exenteration requires complete resection of the tumor with negative margins to be considered a curative surgery. The pur- pose of this review is to assess the optimal preoperative evaluation and surgical approach in patients with recurrent cervical cancer to in- crease the chances of achieving a curative surgery with decreased morbidity and mortality in the era of concurrent chemoradiotherapy. Methods: Review of English publications pertaining to cervical cancer within the last 25 years were included using PubMed and Cochrane Library searches. Results: Modern imaging (MRI and PET-CT) does not accurately identify local extension of microscopic disease and is inadequate for pre- operative planning of extent of resection.
    [Show full text]
  • Obliterative Lefort Colpocleisis in a Large Group of Elderly Women
    Obliterative LeFort Colpocleisis in a Large Group of Elderly Women Salomon Zebede, MD, Aimee L. Smith, MD, Leon N. Plowright, MD, Aparna Hegde, MD, Vivian C. Aguilar, MD, and G. Willy Davila, MD OBJECTIVE: To report on anatomical and functional satisfaction. Associated morbidity and mortality related outcomes, patient satisfaction, and associated morbidity to the procedure are low. Colpocleisis remains an and mortality in patients undergoing LeFort colpocleisis. excellent surgical option for the elderly patient with METHODS: This was a retrospective case series of advanced pelvic organ prolapse. LeFort colpocleisis performed from January 2000 to (Obstet Gynecol 2013;121:279–84) October 2011. Data obtained from a urogynecologic DOI: http://10.1097/AOG.0b013e31827d8fdb database included demographics, comorbidities, medi- LEVEL OF EVIDENCE: III cations, and urinary and bowel symptoms. Prolapse was quantified using the pelvic organ prolapse quantification y 2050, the elderly will represent the largest section (POP-Q) examination. Operative characteristics were Bof the population and pelvic floor dysfunction is recorded. All patients underwent pelvic examination projected to affect 58.2 million women in the United and POP-Q assessment at follow-up visits. Patients also States. We thus can expect to see a increase in the were asked about urinary and bowel symptoms as well as demand for urogynecologic services in this popula- overall satisfaction. All intraoperative and postoperative tion.1,2 Most women older than age 65 years are surgical complications were recorded. afflicted with at least one chronic medical condition, RESULTS: Three hundred twenty-five patients under- and, with the rate of comorbid conditions increasing went LeFort colpocleisis.
    [Show full text]
  • About Ovarian Cancer Overview and Types
    cancer.org | 1.800.227.2345 About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Ovarian Cancer? Research and Statistics See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done. ● Key Statistics for Ovarian Cancer ● What's New in Ovarian Cancer Research? What Is Ovarian Cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer and can spread. To learn more about how cancers start and spread, see What Is Cancer?1 Ovarian cancers were previously believed to begin only in the ovaries, but recent evidence suggests that many ovarian cancers may actually start in the cells in the far (distal) end of the fallopian tubes. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 What are the ovaries? Ovaries are reproductive glands found only in females (women). The ovaries produce eggs (ova) for reproduction. The eggs travel from the ovaries through the fallopian tubes into the uterus where the fertilized egg settles in and develops into a fetus. The ovaries are also the main source of the female hormones estrogen and progesterone. One ovary is on each side of the uterus. The ovaries are mainly made up of 3 kinds of cells. Each type of cell can develop into a different type of tumor: ● Epithelial tumors start from the cells that cover the outer surface of the ovary.
    [Show full text]
  • High Number of Endometrial Polyps Is a Strong Predictor of Recurrence: findings of a Prospective Cohort Study in Reproductive-Age Women
    ORIGINAL ARTICLE: GYNECOLOGY AND MENOPAUSE High number of endometrial polyps is a strong predictor of recurrence: findings of a prospective cohort study in reproductive-age women Fang Gu, M.D.,a Huanxiao Zhang, M.D.,b Simin Ruan, M.D.,c Jiamin Li, M.D.,d Xinyan Liu, M.D.,a Yanwen Xu, M.D.,a,e and Canquan Zhou, M.D.a,e a Center for Reproductive Medicine, Department of Obstetrics and Gynecology, b Division of Gynecology, Department of Obstetrics and Gynecology, and c Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, First Affiliated Hospital of Sun Yat-sen University; d Department of Obstetrics and Gynecology, Second Affiliated Hospital of Guangzhou Medical College; and e Key Laboratory of Reproductive Medicine of Guangdong Province, Guangzhou, People's Republic of China Objective: To compare the incidence of recurrence between a cohort with a high number (R6) of endometrial polyps (EPs) and a single- EP cohort among reproductive-age patients after polypectomy. Design: Prospective observational cohort study. Setting: Single university center. Patient(s): Premenopausal women who underwent hysteroscopic endometrial polypectomy were recruited. Intervention(s): Patients underwent a transvaginal ultrasound scan every 3 months after polypectomy to detect EP recurrence. Kaplan- Meier and Cox regression models were used to compare the risk of recurrence between the two cohorts and analyze the potential risk factors for EP recurrence. Main Outcome Measure(s): EP recurrence rate. Result(s): The study enrolled 101 cases with a high number of EP and 81 cases with a single EP. All baseline parameters were similar except that the high number of EP cohort had a slightly lower mean age than the single EP cohort (33.5 [range 30.0–39.0] vs.
    [Show full text]
  • Pelvic Exenteration for the Management of Pelvic Malignancies
    Chapter 7 Pelvic Exenteration for the Management of Pelvic Malignancies Daniel Paramythiotis, Konstantinia Kofina and Antonios Michalopoulos Additional information is available at the end of the chapter http://dx.doi.org/10.5772/61083 Abstract Pelvic exenteration is a surgical procedure first described by Brunschwig in 1948 as a curative or palliative treatment for pelvic and perineal tumors. It is actually a radical operation, involving en bloc resection of pelvic organs, including reproductive structures, bladder, and rectosigmoid. In patients with recurrent cervical and vaginal malignancy, it is associated with a 5-year survival of more than 50%. In spite of advances in surgical management, consequences such as stomas, are still frequently unavoidable for radical tumor excision. Most candidates for this procedure have been diagnosed with recurrent cervical cancer that has previously been treated with surgery and radiation, or radiation alone. Complications of pelvic exenteration are more severe than those of standard resection of a colorectal carcinoma, so it is not commonly performed, including wound infection, wound dehiscence (also described as burst abdomen) the creation of fistulae (perineal-fecal, uretero-vaginal, between conduit and perineal wound), urinary tract infections, perineal hernias and intestinal obstruction. Patients need to be carefully selected and counseled about risks and long-term issues related to the surgery. A comprehensive evaluation is required in order to exclude unresectable or metastatic disease. Evolution of the technique through laparoscopy and minimally invasive surgery may result in a reduction of morbidity and mortality. Keywords: Pelvic exenteration, gynecologic cancer 1. Introduction Pelvic exenteration was first described by Brunschwig and his colleagues of New York’s Memorial Hospital in 1948 [1] and was initially performed as a palliative surgical intervention © 2015 The Author(s).
    [Show full text]
  • 2021 – the Following CPT Codes Are Approved for Billing Through Women’S Way
    WHAT’S COVERED – 2021 Women’s Way CPT Code Medicare Part B Rate List Effective January 1, 2021 For questions, call the Women’s Way State Office 800-280-5512 or 701-328-2389 • CPT codes that are specifically not covered are 77061, 77062 and 87623 • Reimbursement for treatment services is not allowed. (See note on page 8). • CPT code 99201 has been removed from What’s Covered List • New CPT codes are in bold font. 2021 – The following CPT codes are approved for billing through Women’s Way. Description of Services CPT $ Rate Office Visits New patient; medically appropriate history/exam; straightforward decision making; 15-29 minutes 99202 72.19 New patient; medically appropriate history/exam; low level decision making; 30-44 minutes 99203 110.77 New patient; medically appropriate history/exam; moderate level decision making; 45-59 minutes 99204 165.36 New patient; medically appropriate history/exam; high level decision making; 60-74 minutes. 99205 218.21 Established patient; evaluation and management, may not require presence of physician; 99211 22.83 presenting problems are minimal Established patient; medically appropriate history/exam, straightforward decision making; 10-19 99212 55.88 minutes Established patient; medically appropriate history/exam, low level decision making; 20-29 minutes 99213 90.48 Established patient; medically appropriate history/exam, moderate level decision making; 30-39 99214 128.42 minutes Established patient; comprehensive history exam, high complex decision making; 40-54 minutes 99215 128.42 Initial comprehensive
    [Show full text]
  • Prohibitin-Induced Obesity Leads to Anovulation and Polycystic Ovary in Mice Sudharsana Rao Ande1,*, Khanh Hoa Nguyen1,*, Yang Xin Zi Xu1 and Suresh Mishra1,2,‡
    © 2017. Published by The Company of Biologists Ltd | Biology Open (2017) 6, 825-831 doi:10.1242/bio.023416 RESEARCH ARTICLE Prohibitin-induced obesity leads to anovulation and polycystic ovary in mice Sudharsana Rao Ande1,*, Khanh Hoa Nguyen1,*, Yang Xin Zi Xu1 and Suresh Mishra1,2,‡ ABSTRACT and Dunphy, 2014). Along with the increase in the prevalence of Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder overweight and obesity in women, there has been an increase in and the most common cause of female infertility. However, its etiology anovulatory infertility (Giviziez et al., 2016). Androulakis et al. and underlying mechanisms remain unclear. Here we report that a (2014) reported that visceral adiposity index is related to the severity transgenic obese mouse (Mito-Ob) developed by overexpressing of anovulation and other clinical features in women with polycystic prohibitin in adipocytes develops polycystic ovaries. Initially, the ovaries. An increase in subcutaneous abdominal fat has also been female Mito-Ob mice were equally fertile to their wild-type littermates. associated with anovulation in women with obesity (Kuchenbecker The Mito-Ob mice began to gain weight after puberty, became et al., 2010). It is believed that anovulatory infertility accounts for significantly obese between 3-6 months of age, and ∼25% of them 25-50% of causes of female infertility (Weiss and Clapauch, 2014). had become infertile by 9 months of age. Despite obesity, female One of the main causes of anovulatory infertility is polycystic Mito-Ob mice maintained glucose homeostasis and insulin sensitivity ovaries (Ben-Shlomo et al., 2008; Messinis et al., 2015).
    [Show full text]
  • Agreement Between Endocervical Brush and Endocervical Curettage in Patients Undergoing Repeat Endocervical Sampling
    Agreement Between Endocervical Brush and Endocervical Curettage in Patients Undergoing Repeat Endocervical Sampling Meredith J. Alston MD David W. Doo MD Sara E. Mazzoni MD MPH Elaine H. Stickrath MD Denver Health Medical Center University of Colorado Department of Obstetrics and Gynecology Background • Women with abnormal Pap tests referred for colposcopy frequently require sampling of the endocervix • ASCCP deems both the endocervical brush (ECB) and the endocervical currette (ECC) appropriate means of collecting endocervical samples (1) • Both have advantages and disadvantages, and it is unclear if one modality is superior Background • ECB has good sensitivity for endocervical lesions, it has poor specificity, ranging from 26- 38%2,3 • ECC has an excellent negative predictive value of 99.4% in women who had a satisfactory colposcopy • ECB is better tolerated by the patient, but runs the risk of contamination from the ectocervix • ECC is less likely to obtain an adequate sample Background • The results from the endocervical sample may influence clinical management after colposcopy. • Certain treatment options for high grade squamous intraepithelial neoplasia are available only to women with negative endocervical sampling. ▫ Ablative techniques ▫ Expectant management Background • Over concerns related to potential complications of excisional treatments, as well as over- treatment, there has been a push to re-introduce ablative techniques and, in appropriate clinical circumstances, expectant management, into the routine treatment of patients with cervical cancer precursors (12). Background • At our institution, it is our concern that due to the possibility of contamination from the ectocervix, a positive ECB may not represent a true positive endocervical sample. • We do not use a sleeve • Positive ECBs return for ECC if otherwise a candidate for ablative therapy or expectant management Objective • To describe the agreement between these two modalities of endocervical sampling.
    [Show full text]
  • Curriculum Vitae
    CURRICULUM VITAE G. WILLY DAVILA, M.D. GUILLERMO H. DAVILA, M.D., FACOG, FPMRS Medical Director, Women and Children’s Services Holy Cross Medical Group Center for Urogynecology and Pelvic Floor Medicine Dorothy Mangurian Comprehensive Women’s Center Holy Cross Health Fort Lauderdale, Florida, USA Academic positions: Affiliate Professor, Florida Atlantic University School of Medicine Clinical Associate Professor, University of South Florida, Dept. of Obstetrics and Gynecology Address: Holy Cross HealthPlex Dorothy Mangurian Comprehensive Women’s Center 1000 NE 56th Street Fort Lauderdale, Florida 33334 Phone (954) 229-8660 FAX (954) 229-8659 Email: [email protected] Education 1976-1979 University of Texas at El Paso, Texas B.S. Biology 1976-1977 University of Bolivia Medical School, La Paz, Bolivia no degree 1979-1983 University of Texas Medical School, Houston, Texas M.D. Residency 1983-1987 University of Colorado Health Sciences Center, Denver, Colorado Obstetrics and Gynecology Postgraduate Training 1989 Gynecological Urology Clinical Preceptorship: Long Beach Memorial Hospital, University of California, Irvine Donald Ostergard, M.D., Director Previous Positions: 1999-2017 Chairman, Department of Gynecology, Cleveland Clinic Florida 1999-2018 Head, Section of Urogynecology and Reconstructive Pelvic Surgery Cleveland Clinic Florida Director, The Pelvic Floor Center at Cleveland Clinic Florida A National Association for Continence (NAFC) Center of Excellence in Pelvic Floor Care Director, Clinical Fellowship program - Urogynecology and Reconstructive Pelvic Surgery (2000-2007) 2015-2016 Clinical Director, Global Patient Services (Weston) Cleveland Clinic Foundation, International Center 2013-2016 Center Director, Obstetrics and Gynecology and Women’s Health Institute (Weston) Cleveland Clinic Foundation 1992-1999 Director, Colorado Gynecology and Continence Center, P.C.
    [Show full text]